Vijaya Diagnostic Centre appointed Ms. Naga Vasudha Tadepalli as Company Secretary & Compliance Officer effective June 01, 2026. The appointment strengthens the company's corporate governance and regulatory compliance framework. Ms. Tadepalli brings over 16 years of extensive experience in corporate secretarial, legal, and regulatory compliance functions across listed and unlisted companies.

Ms. Tadepalli is an Associate Member of the Institute of Company Secretaries of India (ICSI) and holds a bachelor's degree in arts and law (B.A., LL.B.) from Osmania University. She possesses significant expertise in ensuring compliance with the Companies Act, 2013, SEBI Regulations, stock exchange requirements, and corporate governance practices. Her experience includes conducting Board and General Meetings, handling corporate actions, ESOPs, preferential issues, rights issues, buybacks, mergers and acquisitions, and regulatory filings with Stock Exchanges, the Ministry of Corporate Affairs, RBI, and other statutory authorities.

Prior to joining Vijaya Diagnostic Centre , Ms. Vasudha served as Company Secretary & Compliance Officer of listed entities, including Cigniti Technologies Limited. She has also worked with reputed corporate secretarial firms and listed companies. She has represented companies before SEBI, NSE, BSE, ROC, and other regulatory authorities.

The appointment was communicated to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Profile of Naga Vasudha Tadepalli

Vijaya Diagnostic Centre Limited has informed the stock exchanges that Mr. Shekhar Prasad Singh and Mr. Satyanaryana Murthy Chavali have ceased to be Non-Executive Independent Directors of the company. The cessation is effective from the close of business hours on May 25, 2026, following the completion of their respective tenures. The company acknowledged the valuable services rendered by the directors during their term.

The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing included detailed disclosures in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Details of the Change

The regulatory filing confirmed that the primary reason for the cessation for both directors was the completion of their tenure.

Directorship and Committee Positions

The filing outlined the directorships and committee positions held by the outgoing directors in other listed entities. Mr. Shekhar Prasad Singh held no directorships or committee positions in listed companies. Mr. Satyanaryana Murthy Chavali held significant roles in Gland Pharma Limited.

The company confirmed that there are no other material reasons for the cessation beyond the completion of tenure.